A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Denenicokin (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 26 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 09 Oct 2013 Planned end date changed from 1 Sep 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top